Association between total bilirubin and bone mineral density level in adolescents

Jing Wu1*, Jiali Su2, Yangyang Wang1, Jianfeng Chen3, Yuanyuan Shang4 and Jing Li5,6

Abstract

Background: Increasing bone mass accumulation in adolescence and obtaining greater peak bone mass is one of the effective methods to prevent osteoporosis in the future. We aimed to examine the association between total bilirubin and bone mineral density (BMD) level in adolescents.

Methods: We used the data from 2005–2010 and 2013–2014 cycles of National Health and Nutrition Examination Survey (NHANES). The BMD levels in the region of lumbar spine and femoral regions, including total femur, femoral neck, trochanter, and intertrochanter were measured. Univariable and multivariable linear regression model were used to assess the relationship between total bilirubin concentration and BMD.

Results: A total of 3741 participants aged 12–19 years were ultimately included in the study. There were 1997 (53.38%) males and 1744 (46.62%) females. Univariate analysis results showed that age, sex, race, education, income, body mass index, dietary calcium intake, and diabetes were correlated with BMD levels. Compared with the lowest quartile of total bilirubin concentration, the highest quartile of total bilirubin concentration was positively associated with BMD levels in the regions of total femur (β = 0.036, 95% CI = 0.021 to 0.050, P < 0.001), femur neck (β = 0.030, 95% CI = 0.016 to 0.044, P < 0.001), trochanter (β = 0.033, 95% CI = 0.019 to 0.046, P < 0.001), intertrochanter (β = 0.040, 95% CI = 0.023 to 0.056, P < 0.001), and lumbar spine (β = 0.032, 95% CI = 0.018 to 0.045, P < 0.001). We also observe the same trend in sensitivity analysis (P for trend < 0.001).

Conclusion: Our study demonstrated that total bilirubin concentration was positively associated with BMD levels in adolescents in United States. Total bilirubin concentration might be a protective marker against bone loss in adolescents.

Keywords: Total bilirubin, Bone mineral density, Adolescents, Cross-sectional

Introduction

Osteoporosis is a global public health problem that can reportedly begin from childhood or adolescence [1, 2]. Adolescence is widely accepted as a critical period of bone development [3]. During this period, the increase of bone mineral density (BMD) leads to a significant increase in bone mass in bone mass, and peak bone mass may be achieved in late adolescence [4–6]. Therefore, developing BMD in adolescence is crucial for adult bone mass accumulation and bone formation. Epidemiological evidence indicates that when peak bone mass increases by 5% in children and adolescents, the risk of osteoporotic fractures decreases by 40%, and when peak bone mass increases by 10%, the risk decreases by 50% [7, 8].

Bilirubin is a by-product of heme catabolism, which has been demonstrated to have anti-inflammatory and antioxidant properties [9–11]. Evidence from many studies indicates that oxidative stress may play a role in the pathogenesis of osteoporosis [12–14]. However, the association between bilirubin concentration and...
BMD and osteoporosis has not been well established, and several studies have reported conflicting results. A cross-sectional study including 918 women at post menopause reported that total bilirubin was positively associated with BMD and a decreased risk of osteoporosis [15]. Another study reported that in healthy middle-aged individuals without liver disease, serum total bilirubin can be used as a protective marker to prevent future bone loss [16]. By contrast, a genome-wide association study (GWAS) revealed that circulating bilirubin levels are not a causal risk factor for osteoporosis or fracture [17]. Furthermore, a study with a small sample size demonstrated that serum bilirubin levels were negatively associated with bone loss at the femoral neck [18].

However, data on the associations between bilirubin concentration and BMD among adolescents are scarce. Therefore, in this study, we investigated the association between total bilirubin concentration and BMD levels in the total femur, femur neck, femur neck, intertrochanter, and lumbar spine regions using data from the United States National Health and Nutrition Examination Survey (NHANES).

Materials and methods
Data source and study population
We used data from the 2005–2010 and 2013–2014 cycles of NHANES. NHANES, a complex nationwide survey, is conducted by the National Center for Health Statistics of the Centers for Disease Control and Prevention (CDC). The aim of this survey is to monitor the health and nutritional status among the US population. Information for demographic, socioeconomic, and health-related factors were ascertained through the interview component. More details information on survey design and methodology are available at http://www.cdc.gov/nchs/nhanes.htm. The NHANES protocol was are required to be evaluated by the National Center for Health Statistics (NCHS) Ethics Review Board.

In the present study, participants aged 12–19 years were eligible for analysis. Furthermore, we limited our analysis to participants with available data on total bilirubin concentration and BMD levels in the regions of total femur, femur neck, femur neck, intertrochanter, and lumbar spine. Finally, a total of 3741 participants were included in our study. Written informed consent was obtained from all participants.

Laboratory analysis
Total bilirubin concentration (mg/dL) was measured on Beckman Synchron LX20 using a timed endpoint diazo method based on the NHANES Laboratory Procedures Manual. The basis of this method is that bilirubin reacts with diazo reagent in the presence of accelerator caffeine, benzoate and acetate to produce azobilirubin, and the absorbance change at 520 nm is monitored at a fixed time interval. The change of absorbance is directly proportional to the concentration of total bilirubin in the serum sample.

Dual-energy x-ray absorptiometry (DEXA) in NHANES was conducted to eligible survey participants at mobile examination center (MEC). The BMD (gm/cm²) measurement was performed by DEXA examinations. The BMD of lumbar spine and femoral regions, including total femur, femoral neck, trochanter, and intertrochanter.

The 2005–2010 DEXA scans were examined using Hologic QDR 4500A fan-beam, while those from 2013 to 2014 were measured by Hologic Discovery® A (Hologic Inc., Marlborough, MA) densitometers.

Covariates
Demographic variables, including age, sex, race, education, and income were self-reported and derived from demographics questionnaires by trained interviewers using the Computer-Assisted Personal Interviewing (CAPI) system. Body mass index (BMI) was calculated as the ratio of weight to the square of the height (kg/m²). The dietary calcium intake (gm/day) was obtained based on the types and amounts of foods and beverages consumed in two nonconsecutive 24-h period before the interview. The presence of diabetes was determined by personal interview data (self-report).

Statistical analysis
The characteristics of study participants were presented using the mean and standard deviations (SDs) (for continuous variable) or proportion (for categorical variable). Univariable and multivariable linear regression model were used to assess the relationship between total bilirubin concentration and BMD levels. The multivariate adjusted model was adjusted for age (continuous), sex (male or female), race (non-Hispanic white, black, Mexican American, other Hispanic, other race/ethnicity or missing), education (less than high school, high school, more than high school, or missing), income (less than $25,000, $25,000–74,999, more than $75,000, or missing), body mass index (underweight, normal weight, overweight, obese, or missing), calcium intake, and diabetes (yes or no). The subgroup analyses were conducted and stratified by sex. All the statistical analyses were conducted using R version 3.3.2 (http://www.R-project.org). Two-sided \( P \) values < 0.05 were considered as statistical significance.
Demographic characteristics of the study population are presented in Table 1. A total of 3741 participants were ultimately included in this cross-sectional analysis. The average age of the participants was 15.46 ± 2.26 years. There were 1997 (53.38%) males and 1744 (46.62%) females. The majority of subjects were non-Hispanic white (29.24%) and Mexican American (29.56%). The average total bilirubin concentration was 0.75 ± 0.34 mg/dL.

The results of univariate analysis for risk factors of the BMD were shown in Table 2. The results showed that age, sex, race, education, income, body mass index, dietary calcium intake, and diabetes were correlated with BMD levels. Furthermore, higher total bilirubin concentration was positively associated with BMD levels in the regions of total femur, femur neck, femur neck, intertrochanter, and lumbar spine.

We took a multiple linear regression analysis to examine the adjusted association between total bilirubin concentration and BMD levels (Table 3). Compared with the lowest quartile of total bilirubin concentration, the highest quartile of total bilirubin concentration was positively associated with BMD levels in the regions of total femur ($\beta = 0.036, 95\% CI = 0.021$ to $0.050, P < 0.001$), femur neck ($\beta = 0.030, 95\% CI = 0.016$ to $0.044, P < 0.001$), trochanter ($\beta = 0.033, 95\% CI = 0.019$ to $0.046, P < 0.001$), intertrochanter ($\beta = 0.040, 95\% CI = 0.023$ to $0.056, P < 0.001$), and lumbar spine ($\beta = 0.032, 95\% CI = 0.018$ to $0.045, P < 0.001$). We also observe the same trend in sensitivity analysis ($P$ for trend < 0.001).

Table 4 shows the adjusted association between total bilirubin concentration and BMD levels in different sex. Compared with the lowest quartile of total bilirubin concentration, the highest quartile of total bilirubin concentration was positively associated with BMD levels in both male and female participants, and the associations were stronger for males than females. Corresponding ORs for BMD levels among males in the regions of total femur, femur neck, femur neck, intertrochanter, and lumbar spine were $0.038 (95\% CI = 0.013$ to $0.063), 0.036 (95\% CI = 0.012$ to $0.060), 0.034 (95\% CI = 0.011$ to $0.057), 0.040 (95\% CI = 0.012$ to $0.069), 0.035 (95\% CI = 0.013$ to $0.058$), respectively.

Discussion
In this study, we investigated the associations between total bilirubin concentration and BMD levels among adolescents aged 12–19 years in the United States. The results revealed that total bilirubin concentration was positively associated with BMD levels in the total femur, femur neck, femur neck, intertrochanter, and lumbar spine regions. Studies have suggested total bilirubin to be a protective biomarker for diabetes, cardiovascular diseases, stroke, and peripheral arterial disease [19–22]. Increasing bone mass accumulation during adolescence and achieving higher peak bone mass can prevent future osteoporosis. Our study agrees with findings that total bilirubin may be a protective marker against bone loss in adolescents.

Our results revealed a positive correlation between bilirubin and BMD, which may be attributed to several possible mechanisms. First, oxidative stress can have detrimental effects on bone metabolism. Reactive oxygen species promote bone resorption by directly stimulating osteoclast differentiation or indirectly increasing the expression of NF-κB ligand receptor activator in osteoblasts [23, 24], and reactive oxygen species inhibit
### Table 2: Univariate analysis of risk factors of the bone mass density

|                  | Statistics | Total femur BMD | Femur neck BMD | Intertrochanter BMD | Lumbar spine BMD |
|------------------|------------|-----------------|----------------|---------------------|-----------------|
|                  | β (95% CI) | P value         | β (95% CI) P value | β (95% CI) P value | β (95% CI) P value |
| Age (year)       |            |                 |                 |                     |                 |
| < 15             | 1416 (37.85) | Ref             | Ref             | Ref                 | Ref             |
| 15–< 20          | 2325 (62.15) | 0.125 (0.115, 0.135) | 0.108 (0.098, 0.117) | 0.078 (0.069, 0.086) | 0.160 (0.149, 0.171) |
| Sex (%)          |            |                 |                 |                     |                 |
| Male             | 1997 (53.38) | Ref             | Ref             | Ref                 | Ref             |
| Female           | 1744 (46.62) | -0.071 (-0.081, -0.061) | -0.055 (-0.064, -0.045) | -0.070 (-0.079, -0.062) | -0.071 (-0.083, -0.059) |
| Body mass index (%) |        |                 |                 |                     |                 |
| Under weight     | 1970 (52.77) | Ref             | Ref             | Ref                 | Ref             |
| Normal weight    | 493 (13.21)  | -0.151 (-0.165, -0.136) | -0.139 (-0.153, -0.126) | -0.109 (-0.122, -0.097) | -0.181 (-0.198, -0.165) |
| Overweight       | 709 (18.99)  | 0.059 (0.047, 0.071) | 0.063 (0.052, 0.075) | 0.039 (0.028, 0.049) | 0.069 (0.055, 0.084) |
| Obese            | 561 (15.03)  | 0.116 (0.103, 0.130) | 0.129 (0.116, 0.141) | 0.082 (0.070, 0.094) | 0.128 (0.113, 0.144) |
| Calcium intake (mg) |        |                 |                 |                     |                 |
| Q1               | 1169 (31.81) | Ref             | Ref             | Ref                 | Ref             |
| Q2               | 1120 (30.48) | -0.000 (-0.013, 0.013) | -0.003 (-0.015, 0.010) | 0.003 (-0.008, 0.014) | -0.004 (-0.020, 0.011) |
| Q3               | 1386 (37.71) | 0.023 (0.011, 0.036) | 0.013 (0.001, 0.025) | 0.028 (0.017, 0.038) | 0.022 (0.007, 0.036) |
| Diabetes (%)     |            |                 |                 |                     |                 |
| No               | 3701 (99.41)| Ref             | Ref             | Ref                 | Ref             |
| Yes              | 22 (0.59)   | 0.015 (-0.053, 0.083) | 0.011 (-0.054, 0.075) | 0.002 (-0.056, 0.060) | 0.023 (-0.056, 0.102) |
| Bilirubin (mg/DL) |        |                 |                 |                     |                 |
| Q1               | 454 (12.14) | Ref             | Ref             | Ref                 | Ref             |
Table 2 (continued)

| Statistics | Total femur BMD | Femur neck BMD | Femur neck BMD | Intertrochanter BMD | Lumbar spine BMD |
|------------|----------------|----------------|----------------|---------------------|-----------------|
| β (95% CI) | P value        | β (95% CI)     | P value        | β (95% CI)          | P value         |
| Q2         | 1236 (33.04)   | 0.012 (-0.005, 0.029) | 0.010 (-0.006, 0.027) | 0.009 (-0.005, 0.024) | 0.015 (-0.005, 0.035) |
| Q3         | 1015 (27.13)   | 0.029 (0.011, 0.047) | 0.019 (0.002, 0.036) | 0.028 (0.013, 0.043) | 0.032 (0.012, 0.053) |
| Q4         | 1036 (27.69)   | 0.056 (0.038, 0.074) | 0.038 (0.021, 0.055) | 0.053 (0.038, 0.068) | 0.063 (0.043, 0.084) |

Table 3 Multivariable adjusted associations among quartile of bilirubin and bone mass density

| Bilirubin (Quintile) | Total femur BMD | Femur neck BMD | Trochanter BMD | Intertrochanter BMD | Lumbar spine BMD |
|----------------------|----------------|----------------|---------------|---------------------|-----------------|
| β (95% CI) P value   | β (95% CI) P value | β (95% CI) P value | β (95% CI) P value | β (95% CI) P value |
| Q1 Ref               |               |               |               |                    |                 |
| Q2 0.010 (-0.003, 0.024) 0.124 | 0.013 (-0.000, 0.026) 0.057 | 0.005 (-0.007, 0.018) 0.374 | 0.014 (-0.001, 0.029) 0.065 | 0.008 (-0.004, 0.021) 0.188 |
| Q3 0.021 (0.007, 0.034) 0.004 | 0.018 (0.004, 0.032) 0.009 | 0.018 (0.005, 0.030) 0.006 | 0.023 (0.007, 0.039) 0.004 | 0.015 (0.002, 0.028) 0.026 |
| Q4 0.036 (0.021, 0.050) <0.001 | 0.030 (0.016, 0.044) <0.001 | 0.033 (0.019, 0.046) <0.001 | 0.040 (0.023, 0.056) <0.001 | 0.032 (0.018, 0.045) <0.001 |
| P for trend          | <0.001        | <0.001        | <0.001        | <0.001              | <0.001          |

Adjust for: age (continuous), sex (male or female), race (non-Hispanic white, black, Mexican American, other Hispanic, other race/ethnicity or missing), education (less than high school, high school, more than high school, or missing), income (less than $ 25,000, $ 25,000–74,999, more than $ 75,000, or missing), body mass index (underweight, normal weight, overweight, obese, or missing), calcium intake, and diabetes (continuous)

Table 4 Multivariable adjusted associations among quartile of bilirubin and bone mass density by sex

| Male | Total femur BMD | Femur neck BMD | Trochanter BMD | Intertrochanter BMD | Lumbar spine BMD |
|------|----------------|----------------|---------------|---------------------|-----------------|
| β (95% CI) P value | β (95% CI) P value | β (95% CI) P value | β (95% CI) P value | β (95% CI) P value |
| Q1 Ref |               |               |               |                    |                 |
| Q2 0.017 (-0.008, 0.043) 0.182 | 0.024 (-0.001, 0.048) 0.058 | 0.011 (-0.012, 0.034) 0.348 | 0.019 (-0.009, 0.048) 0.188 | 0.019 (-0.003, 0.042) 0.096 |
| Q3 0.029 (0.004, 0.055) 0.24 | 0.028 (0.003, 0.052) 0.027 | 0.027 (0.004, 0.050) 0.023 | 0.030 (0.001, 0.059) 0.043 | 0.024 (0.001, 0.046) 0.039 |
| Q4 0.038 (0.013, 0.063) 0.003 | 0.036 (0.012, 0.060) 0.004 | 0.034 (0.011, 0.057) 0.003 | 0.040 (0.012, 0.069) 0.006 | 0.035 (0.013, 0.058) 0.002 |
| P for trend | <0.001        | <0.001        | <0.001        | <0.001              | <0.001          |

| Female | Total femur BMD | Femur neck BMD | Trochanter BMD | Intertrochanter BMD | Lumbar spine BMD |
|--------|----------------|----------------|---------------|---------------------|-----------------|
| β (95% CI) P value | β (95% CI) P value | β (95% CI) P value | β (95% CI) P value | β (95% CI) P value |
| Q1 Ref |               |               |               |                    |                 |
| Q2 0.003 (-0.011, 0.017) 0.690 | 0.004 (-0.010, 0.018) 0.586 | -0.000 (-0.014, 0.013) 0.946 | 0.007 (-0.010, 0.023) 0.424 | -0.002 (-0.016, 0.012) 0.814 |
| Q3 0.008 (-0.008, 0.023) 0.348 | 0.009 (-0.007, 0.025) 0.278 | 0.004 (-0.010, 0.019) 0.548 | 0.010 (-0.008, 0.028) 0.29 | 0.003 (-0.012, 0.019) 0.683 |
| Q4 0.021 (0.003, 0.038) 0.020 | 0.018 (0.000, 0.035) 0.048 | 0.022 (0.006, 0.038) 0.007 | 0.022 (0.002, 0.042) 0.032 | 0.015 (-0.002, 0.032) 0.091 |
| P for trend | 0.016        | 0.036        | 0.005        | 0.033                | 0.063           |
| P for interaction | 0.116        | 0.177        | 0.123        | 0.146                | 0.059           |

Adjust for: age (continuous), race (non-Hispanic white, black, Mexican American, other Hispanic, other race/ethnicity or missing), education (less than high school, high school, more than high school, or missing), income (less than $ 25,000, $ 25,000–74,999, more than $ 75,000, or missing), body mass index (underweight, normal weight, overweight, obese, or missing), calcium intake, and diabetes (continuous)
osteogenesis by regulating redox-sensitive signal pathways [25]. Total bilirubin is an effective antioxidant and can eliminate various forms of free radical oxygen species and inhibit the oxidation of lipids and lipoproteins [15, 26]. Furthermore, osteoporosis caused by oxidative stress may be related to endothelial dysfunction and decreased blood flow in bone tissue [27]; bilirubin can inhibit the activation and dysfunction of vascular endothelium in response to proinflammatory stress [28]. Second, bilirubin plays an antiinflammatory and immunomodulatory role; it protects the body from endotoxin-induced inflammation, down-regulating the expression of adhesion molecules and inhibiting the infiltration of inflammatory cells [9, 10]. In addition, proinflammatory cytokines are key mediators of inflammatory responses and have been demonstrated to regulate bone metabolism [29]. Interleukin-6 (IL-6), which is produced by osteoblasts, monocytes, and T cells, has been reported to promote osteoclast differentiation and activation [30]. Furthermore, IL-6 is related to the pathogenesis of various metabolic bone diseases [31, 32]. Tumor necrosis factor-α (TNF-α) has been reported to be involved in nontumor-induced osteopenia as well as in stimulating bone resorption and inhibiting bone formation [33, 34].

Similar to that presented in the present study, several lines of evidence have suggested that total bilirubin was positively associated with BMD in adults [15, 16]. However, conflicting results have been reported regarding the associations between total bilirubin and BMD levels. Animal experiments and population-based studies indicated that hyperbilirubinemia is not the main factor influencing BMD in patients with chronic liver disease [35]. Bagur et al. also reported no significant association between high bilirubin levels and lumbar BMD in patients with primary biliary cirrhosis [36]. Furthermore, several studies have demonstrated a significant negative correlation between total bilirubin and BMD levels [18, 37]. A cross-sectional, case–control pilot study observed that patients with Gilbert’s syndrome characterized by elevated unconjugated bilirubin tended to have decreased BMD, particularly among older individuals [38]. These inconsistent associations may have been caused by differences in study populations. Most studies with inconsistent findings have only included patients with chronic liver diseases and primary biliary cirrhosis. Because total bilirubin concentration is a key indicator of liver dysfunction, the degree of hepatocyte injury, and prognosis, the results of the aforementioned studies may have been significantly affected by the severity of liver disease in the study populations.

Notably, several studies have revealed a U-shaped association between total bilirubin concentration and coronary heart disease [39, 40], telomere length [41], and all-cause mortality [42]. These findings suggest bilirubin’s threshold effect on bone health. Furthermore, bilirubin may exert a protective effect against oxidative stress–related diseases under normal physiological conditions. When the total bilirubin level exceeds the normal physiological range, it may lead to harmful consequences, including disturbed bone formation related to osteoblast dysfunction. This also explains the significant negative correlation between increased bilirubin and BMD in people with chronic liver disease [16]. Ruiz-Gaspa et al. verified this finding and reported that high concentrations of bilirubin (5.8 mg/dL) can lower the viability, differentiation, and mineralization of osteoblasts [43].

This is the first study, to our knowledge, to demonstrate associations between total bilirubin and BMD levels among adolescents. The results have suggested a weak but significant positive association between bilirubin and BMD level. Furthermore, our analysis was based on data from a large, nationally representative survey, in contrast to those in other studies. Because raising bilirubin levels is not recommended, using a randomized controlled trial to explore the associations between total bilirubin levels and osteoporosis is impossible. Therefore, further high-quality prospective cohort studies are required to verify our findings. The present study also has several limitations. First, the cross-sectional research design precluded causal analysis. Second, although multiple covariates were adjusted for, our findings may have been affected by residual confounding confounders, such as drug therapy, physical activity, genetical factors, and potential chronic liver diseases.

In conclusion, the present study demonstrated a significant positive association between total bilirubin concentration and BMD levels in the total femur, femur neck, femur neck, intertrochanter, and lumbar spine regions among adolescents aged 12–19 years in the United States. Total bilirubin concentration may be a protective marker against bone loss in adolescents.

Acknowledgements
We thank the National Health and Nutrition Examination Survey for the permission for use of the data of the NHANES 2005–2010, 2013–2014.

Authors’ contributions
JW contributed to study design, data analysis, and drafted the manuscript; JS and JC contributed to review and editing the manuscript; YS and JL contributed to revision of the original report. All authors read and approved the final manuscript.

Funding
The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.

Availability of data and materials
The datasets analyzed during the current study are available in the website of the NHANES: https://www.cdc.gov/nchs/index.htm.
Declarations

Ethics approval and consent to participate
This study was approved by the Institutional Review Board of the National Center for Health Statistics. All participants gave their written informed consent. All authors declared that all methods in this study were carried out in accordance with relevant guidelines and regulations.

Consent for publication
The authors consent the publication.

Competing interests
The authors declare that there is no competing interests.

Author details
1Department of Cadre Ward 2, the Second Affiliated Hospital of Harbin Medical University, Harbin 150001, China. 2Department of Cadre Ward 3, the Second Affiliated Hospital of Harbin Medical University, Harbin 150001, China. 3Department of Experimental Animal Center, the Second Affiliated Hospital of Harbin Medical University, Harbin 150081, China. 4Department of Neurosurgical Ward, the Second Affiliated Hospital of Harbin Medical University, Harbin 150081, China. 5Department of Traditional Chinese Medicine, The Second Affiliated Hospital of Harbin Medical University, Harbin 150081, China. 6Department of Traditional Chinese Medicine, The Second Affiliated Hospital of Harbin Medical University, Harbin 150001, China. 7Department of Cadre Ward 2, the Second Affiliated Hospital of Harbin Medical University, Harbin 150001, China. 8Department of Neurosurgical Ward, the Second Affiliated Hospital of Harbin Medical University, Harbin 150081, China. 9Department of Traditional Chinese Medicine, The Second Affiliated Hospital of Harbin Medical University, Harbin 150081, China.

Received: 16 April 2022   Accepted: 22 June 2022

Published online: 04 July 2022

References
1. Yang X, Zhai Y, Zhang J, Chen JY, Liu D, Zhao WH. Combined effects of physical activity and calcium on bone health in children and adolescents: a systematic review of randomized controlled trials. World J Pediatr. 2020;16(4):356–65.
2. Pan K, Tu R, Yao X, Zhu Z. Associations between serum calcium, 25(OH)D level and bone mineral density in adolescents. Adv Rheumatol. 2021;61(1):16.
3. Smith TJ, Lanham-New SA, Hart KH. Vitamin D in adolescents: are current recommendations enough? J Steroid Biochem Mol Biol. 2017;173:265–72.
4. Baxter-Jones AD, Faulkner RA, Forwood MR, Mirwald RL, Bailey DA. Bone mineral accrual from 8 to 30 years of age: an estimation of peak bone mass. J Bone Miner Res. 2011;26(8):1279–309.
5. van der Sluis IM, de Muinck Keizer-Schrama SM. Osteoporosis in childhood: bone density of children in health and disease. J Pediatr Endocrinol Metab. 2002;14(7):817–32.

Causal associations between serum bilirubin levels and decreased stroke risk: a two-sample mendelian randomization study. Arterioscler Thromb Vasc Biol. 2020;40(2):437–45.
8. Goulding A, Jones IE, Taylor RW, Manning PJ, Williams SM. More broken bone resorption and inhibition of bone formation in vitro by human vascular endothelial activation and dysfunction. Arterioscler Thromb Vasc Biol. 2002;12(3):150258.
9. van der Sluis IM, de Muinck Keizer-Schrama SM. Osteoporosis in childhood: bone density of children in health and disease. J Pediatr Endocrinol Metab. 2001;14(7):817–32.
10. Zibibna L, Jenko-Praznikar Z, Petelin A. Serum bilirubin levels in over-weight and obese individuals: the importance of anti-inflammatory and antioxidant responses. Antioxidants (Basel). 2021;10(9):1352.
11. Tran DT, Jeong YY, Kim JM, Bae HB, Son SK, Kwav SH. The anti-inflammatory role of bilirubin on “two-hit” sepsis animal model. Int J Mol Sci. 2020;21(22):8650.
12. Yao Q, Jiao X, Huang ZW, Lan QH, Wang LF, Chen R, Li XZ, Kou L, Xu HL, Zhao YZ. Bilirubin improves the quality and function of hypothermic preserved islets by its antioxidative and anti-inflammatory effect. Transplantation. 2019;103(12):2486–96.
13. Almeida M, Porter RM. Sirtuins and FoxOs in osteoporosis and osteoarthritis. Bone. 2019;121:284–92.
14. Kimball JS, Johnson JP, Carlson DA. Oxidative stress and osteoporosis. J Bone Joint Surg Am. 2021;103(15):1451–61.
15. Mohammad NV, Ima-Nirwana S, Chin KY. Are oxidative stress and inflammation mediators of bone loss due to estrogen deficiency? A review of current evidence. Endocr Metab Immune Disord Drug Targets. 2020;20(9):1478–87.
16. Bian LQ, Li RZ, Zhang ZY, Jin YJ, Kang HW, Fang ZZ, Park YS, Cho YH. Effects of total serum bilirubin on the prevalence of osteoporosis in postmenopausal women without potential liver disease. J Bone Miner Metab. 2013;31(6):637–43.
17. Kim BJ, Koh JM, Ahn SH, Lee SH, Kim EH, Bae SJ, Kim HK, Choe JW, Kim GS. High serum total bilirubin as a protective factor against hip bone loss in healthy middle-aged men. Calcif Tissue Int. 2013;92(6):501–8.
18. Zhao J, Zhang M, Quan Z, Deng F, Li Y, He B. Systematic influence of circulating bilirubin levels on osteoporosis. Front Endocrinol (Lausanne). 2021;12:719920.
19. Ormamottiri S, Ljunggren O, Malmim H, Michaelsson K, Loof L. Increased rate of bone loss at the femoral neck in patients with chronic liver disease. Eur J Gastroenterol Hepatol. 2002;14(1):45–8.
20. Kwon YJ, Lee YJ, Park BJ, Hong KW, Jung DH. Total serum bilirubin and 8-year incident type 2 diabetes mellitus. The Korean Genome and Epidemiology Study. Diabetes Metab. 2018;44(4):346–53.
21. Choi Y, Lee SJ, Spiller W, Jung KJ, Lee JY, Kimm H, Back JH, Lee S, Lee SH. Causal associations between serum bilirubin levels and decreased stroke risk: a two-sample mendelian randomization study. Arterioscler Thromb Vasc Biol. 2020;40(2):437–45.
22. Kunutsor SK, Bakker SJ, Gansevoort RT, Chowdhury R, Dullaart RP. Circulating total bilirubin and risk of incident cardiovascular disease in the general population. Arterioscler Thromb Vasc Biol. 2015;35(3):716–24.
23. Ozeki M, Morita H, Miyamura M, Fujisaka T, Fujita SI, Ito T, Shibata K, Tanaka S, Sohmiya K, Hoshiga M, et al. High serum bilirubin is associated with lower prevalence of peripheral arterial disease among cardiac patients. Clin Chim Acta. 2018;476:60–6.
24. Bai XC, Lu D, Liu AL, Zhang ZM, Li XM, Zou ZP, Zheng BL, Luo SQ. Reactive oxygen species stimulates receptor activator of NF-kappaB ligand expression in osteoblast. J Biol Chem. 2005;280(17):17497–506.
25. Lee NK, Choi YG, Baik JY, Han SY, Jeong DW, Bae YS, Kim N, Lee SY. A crucial role for reactive oxygen species in RANKL-induced osteolast differentiation. Blood. 2005;106(3):652–9.
26. Wauquier F, Leotoing L, Coxam Y, Guichieux J, Witrant Y. Oxidative stress in bone remodelling and disease. Trends Mol Med. 2009;15(10):468–77.
27. Woon YJ, Lee HS, Lee JW. Direct bilirubin is associated with low-density lipoprotein subfractions and particle size in overweight and centrally obese women. Nutr Metab Cardiovasc Dis. 2018;28(10):1021–8.
28. Sanchez-Rodriguez MA, Ruiz-Ramos M, Correa-Munuez E, Mendoza-Nunez VM. Oxidative stress as a risk factor for osteoporosis in elderly Mexicans as characterized by antioxidant enzymes. BMC Musculoskeletal Disord. 2007;8:124.
29. Kawamura K, Ishikawa K, Wada Y, Kiruma S, Matsumoto H, Kohro T, Itabe H, Kodama T, Maruyama Y. Bilirubin from heme oxygenase-1 attenuates the anti-inflammatory role of bilirubin on “two-hit” sepsis animal model. Int J Mol Sci. 2020;21(22):8650.
30. van der Sluis IM, de Muinck Keizer-Schrama SM. Osteoporosis in childhood: bone density of children in health and disease. J Pediatr Endocrinol Metab. 2001;14(7):817–32.
31. Wang J, Chen J, Zhang B, Jia X. IL-6 regulates the bone metabolism and inflammatory microenvironment in aging mice by inhibiting Sestr7. Acta Histochem. 2021;123(5):151718.
32. Wang T, He C. Pro-inflammatory cytokines: The link between obesity and osteoarthritis. Cytokine Growth Factor Rev. 2018;44:38–50.
33. Sanchez-Rodriguez MA, Ruiz-Ramos M, Correa-Munuez E, Mendoza-Nunez VM. Oxidative stress as a risk factor for osteoporosis in elderly Mexicans as characterized by antioxidant enzymes. BMC Musculoskeletal Disord. 2007;8:124.
36. Bagur A, Mautalen C, Findor J, Sorda J, Somoza J. Risk factors for the development of vertebral and total skeleton osteoporosis in patients with primary biliary cirrhosis. Calcif Tissue Int. 1998;63(5):385–90.
37. Menon KV, Angulo P, Weston S, Dickson ER, Lindor KD. Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. J Hepatol. 2001;35(3):316–23.
38. Minuk GY, Greenberg R, Uhanova J, Hawkins K, Leslie WD. Bone mineral densities in individuals with Gilbert’s syndrome: a cross-sectional, case-control pilot study. Can J Gastroenterol. 2009;23(6):431–6.
39. Lai X, Fang Q, Yang L, Chen X, Wang H, Ma L, Guo W, Liu M, Yang H, Zhang C, et al. Direct, indirect and total bilirubin and risk of incident coronary heart disease in the Dongfeng-Tongji cohort. Ann Med. 2018;50(1):16–25.
40. Li C, Wu W, Song Y, Xu S, Wu X. The nonlinear relationship between total bilirubin and coronary heart disease: a dose-response meta-analysis. Front Cardiovasc Med. 2021;8:761520.
41. Hao L, Chen Q, Chen X, Zhou Q. Association of serum total bilirubin concentration with telomere length: the National Health and Nutrition Examination Survey. Oxid Med Cell Longev. 2021;2021:4688900.
42. Lind L, Zanetti D, Hogman M, Sundman L, Ingelsson E. Commonly used clinical chemistry tests as mortality predictors: Results from two large cohort studies. PLoS One. 2020;15(11):e0241558.
43. Ruiz-Gaspa S, Martinez-Ferrer A, Guanabens N, Dubreuil M, Peris P, Enjuanes A, Martinez de Osaba MJ, Alvarez L, Monegal A, Combalia A, et al. Effects of bilirubin and sera from jaundiced patients on osteoblasts: contribution to the development of osteoporosis in liver diseases. Hepatology. 2011;54(6):2104–13.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.